## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

3235-0287

OMB Number:

STATEMENT O	CHANGES	IN BENEFICIAL	OWNERSHIP
-------------	---------	---------------	-----------

Section obligat	n 16. Form	io longer subject to 4 or Form 5 ontinue. <i>See</i>	STA	d pursuant to Section 16(a) of the Securities Exchange Act of 1934												3235-0287 1 0.5	
1. Name and Address of Reporting Person KNOBELMAN DEBORAH					or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol Senti Biosciences, Inc. [SNTI]									able)	) Persor	10% Ov Other (s	wner (specify
		(First) SCIENCES, IN DRIVE FIRST			3. Date of Earliest Transaction (Month/Day/Year) 02/01/2024						- X Ch	below) ief Financ		below; eer / Head of C lopment			
(Street) SOUTH SAN FRANCISCO CA 94080					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)		(State)	(Zip)		Rule 10b5-1(c) Transaction Indication						a contract	, instruction	or written pl	an that is	s intended t	o satisfy	
			Table I - No	n-Deriv	ative S	ecurities Acc	quired,	Dis	posed o	of, o	r Bene	ficially	Owned				
Date				action Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (	Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			5. Amour Securitie Beneficia Owned F	s Ily ollowing			7. Nature of Indirect Beneficial Ownership	
							Code	v	Amount		(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common Stock 02/0			02/01	/2024		Α		101,000 <sup>(1)</sup>		A	\$ <mark>0</mark>	131,000		D			
			Table II -			curities Acqu lls, warrants,							wned				
1. Title of Derivative	2. Conversi	3. Transactio	action 3A. Deemed 4. 5. Number of 6. Date Exercisable and 7. Title and Execution Date, Transaction Derivative Expiration Date of Securities				8. Price of Derivative	9. Numbe derivative		10. Ownership	11. Nature of Indirect						

1. Title of Derivative Security (Instr. 3)		2. Conversion or Exercise Price of Derivative Security	3. Iransaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. If the and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)			
	Stock Option (Right to Buy)	<b>\$</b> 0.46	02/01/2024		A		152,000		(2)	01/31/2034	Common Stock	152,000	\$0	152,000	D		

## Explanation of Responses:

1. The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Senti Biosciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. All of the shares underlying the award vest in three substantially equal annual installments over three years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.

2. The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date. **Remarks:** 

/s/ Mike Rhee, attorney-in-fact 02/02/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{*}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.